Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Duke Energy Corp (DUK) vs BIO-TECHNE Corp (TECH) Price & Performance

Duke Energy CorpTrade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

Duke Energy Corp vs BIO-TECHNE Corp — how do they compare? Duke Energy Corp trades at $116.14 (market cap $91.10B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Duke Energy Corp is far larger — about 8× BIO-TECHNE Corp's market cap, and Duke Energy Corp pays the higher dividend (3.71%). Which is the better fit depends on your goals — on Pluang, investors hold Duke Energy Corp for 74 Days and BIO-TECHNE Corp for 63 Days on average.

DUKTECH
Market Cap
$91.10B$11.36B
Volume
4,199,0505,390,331
Sector
UtilitiesHealth
52-Week High
$133.46$72.61
52-Week Low
$113.23$43.31
Typical Hold Time
74 Days63 Days
Enterprise Value
$183.61B$11.39B
Dividend Yield
3.71%0.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Duke Energy Corp

Duke Energy (DUK) trades at $115.50, down 0.14% with a bearish technical signal. The company demonstrates strong fundamentals with consistent earnings beats, 15.78% net income margin, and stable dividend payments. Recent news highlights Duke's positioning in data center growth opportunities while facing pressure from rising Treasury yields. The stock trades below analyst consensus target of $134.44 with 43.75% buy ratings.

DUK offers income investors a stable utility play with growth potential from data center demand, though rising interest rates and high debt levels present headwinds. The current valuation at 17.6 P/E appears reasonable given the company's consistent profitability and dividend reliability. Upside potential exists if data center contracts materialize as projected.

BIO-TECHNE Corp

TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.

The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Duke Energy Corp

Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure

Read more on DUK →

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH →